Research Article

Circulating MicroRNA-122 for the Diagnosis of Hepatocellular Carcinoma: A Meta-Analysis

Xiao-Fei Zhao, Ning Li, Dong-Dong Lin, and Li-Bo Sun

1Department of General Surgery and Liver Transplantation Center, Capital Medical University Affiliated Youan Hospital, Beijing 100069, China
2Capital Medical University Affiliated Youan Hospital, Beijing 100069, China

Correspondence should be addressed to Ning Li; yayypwzx@163.com

Received 24 October 2019; Revised 17 January 2020; Accepted 11 February 2020; Published 27 March 2020

Academic Editor: Naohiko Masaki

Copyright © 2020 Xiao-Fei Zhao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Circulating microRNA-122 (miR-122) has been recognized as a marker of hepatocellular carcinoma (HCC). The current meta-analysis was performed to quantitatively evaluate the diagnostic performance of circulating miR-122 for HCC.

Methods. Related studies that evaluated the diagnostic performance of circulating miR-122 determined from pathophysiological examination for HCC were obtained by systematic searches of the PubMed and Embase databases. A randomized fixed effects model was applied according to the heterogeneity among studies. The pooled sensitivity, specificity, and area under the summary receiver operating characteristic curve (AUC) were calculated to evaluate the diagnostic accuracy. Publication bias was detected by Deeks’ funnel plot asymmetry test.

Results. Thirteen studies providing data for 920 HCC patients and 1217 controls were included in the meta-analysis. The pooled sensitivities, specificities, and AUCs of serum miR-122 were 0.76, 0.75, and 0.82, respectively, for discriminating HCC patients from overall controls; 0.85, 0.83, and 0.91, respectively, for discriminating HCC patients from healthy controls; 0.79, 0.82, and 0.87, respectively, for discriminating HCC from HBV or HCV infection; and 0.65, 0.75, and 0.74, respectively, for discriminating HCC from liver cirrhosis or dysplastic nodule formation. No significant publication bias was detected.

Conclusions. Serum miR-122 confers moderate efficacy for discriminating HCC patients from healthy controls or patients with HBV or HCV infection, but not for discriminating HCC patients from those with liver cirrhosis or dysplastic nodule formation.

1. Introduction

Hepatocellular carcinoma (HCC) accounts for more than 80% of cases of primary liver cancer [1], and the prognosis of patients with HCC depends on the staging of the disease. The 5-year survival of patients with early-stage HCC was reported to be as high as 75%, whereas the 1-year survival of patients with widespread HCC was reported to be less than 10%, which highlights the importance of early diagnosis [1, 2].

Currently, clinical screening strategies for HCC mainly involve ultrasonography [3, 4]. However, the diagnostic performance of ultrasonography for early HCC is poor due to its low sensitivity [5]. Other imaging modalities such as computer tomography (CT) and magnetic resonance imaging (MRI) have limited value for HCC screening because of the risk of radiation exposure or high expense [3, 4]. Serum biomarkers may be convenient and effective for early diagnosis of HCC. However, increased circulating alpha fetoprotein (AFP), the most commonly used circulating biomarker for HCC, has been observed in patients without HCC, such as those with chronic hepatitis B or C, suggesting the poor specificity of AFP for HCC [3, 6].

Recent advances in biomedical research have demonstrated that microRNAs (miRNAs), an endogenous group of small noncoding RNAs that negatively regulate gene expression at the posttranscriptional level, are involved in many cellular processes, including carcinogenesis [7]. miRNAs are highly stable and measurable from various tissues, including the peripheral circulation, which makes them...
potential biomarkers for cancer screening in clinics \[8, 9\]. MicroRNA-122 (miR-122) has been demonstrated to be involved in the process of hepatocarcinogenesis, and differences in the circulating level of miR-122 have been observed in HCC patients compared with control individuals \[8, 10\]. Although accumulating studies have evaluated the potential diagnostic performance of miR-122 for HCC, quantitative meta-analyses that summarize the diagnostic efficacy of miR-122 for HCC are still needed. In a previous meta-analysis that included four studies \[11\textendash}14\], Huang et al. concluded that serum miR-122 confers promising diagnostic efficacy for HCC \[15\]. However, due to the small number of studies included, they were unable to evaluate the efficacy of circulating miR-122 for discriminating HCC patients from various control patient populations \[15\]. Since the publication of their meta-analysis, several additional studies regarding the diagnostic efficacy of miR-122 for HCC have been published \[16\textendash}24\]. Therefore, we aimed to quantitatively evaluate the potential diagnostic performance of circulating miR-122 for HCC in an updated meta-analysis. Moreover, we explored whether circulating miR-122 confers similar efficacy for discriminating HCC patients from healthy controls, HCC patients from those with HBV or HCV infection, and HCC patients from those with liver cirrhosis.

2. Methods

2.1. Database Searches. This systematic review and meta-analysis was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement \[25\] and Cochrane Handbook \[26\]. The literature reports were obtained via electronic searches of the PubMed (MEDLINE) and Embase databases using the following terms: “microRNA-122,” “miRNA-122,” or “miR-122,” combined with “hepatocellular cancer,” “hepatocellular tumor,” “hepatocellular carcinoma,” “hepatocellular neoplasm,” “liver cancer,” “liver tumor,” “liver carcinoma,” “liver neoplasm,” or “HCC,” with a limitation of studies in humans. The date of the final database search was March 12, 2019. The reference lists of relevant original and review articles were manually searched for potential studies.

2.2. Inclusion and Exclusion Criteria. The following inclusion criteria were applied: (1) full-length article published in English; (2) histopathological examination used as the referenced standard for HCC diagnosis; (3) studies aimed at evaluating the diagnostic performance of circulating miR-122 for HCC diagnosis; and (4) reported data being adequate for extraction or calculation of the true- and false-positive values as well as true- and false-negative values for HCC diagnosis with miR-122 as determined by histopathological examination. Review articles, repeated reports, and preclinical studies were excluded.

2.3. Data Extraction and Quality Assessment. The literature search, data extraction, and quality assessment were independently performed by two authors, with discrepancies resolved by discussion with the corresponding author. The following data were extracted: name of the first author; year of publication; study location; number, age, and gender of HCC patients and controls; characteristics of controls; and miR-122 sampling and measurement methods. True- and false-positive data and true- and false-negative data for the diagnosis of HCC based on miR-122 were extracted or calculated for meta-analysis. The quality evaluation was performed with the QUADAS (quality assessment tool for diagnostic accuracy studies) scale \[27\]. The QUADAS scale is a validated tool for quality evaluation of the diagnostic accuracy studies, with the highest score of 14 indicating optimal study quality.

2.4. Statistical Analysis. The summary sensitivity and specificity were calculated from \(2 \times 2\) forms with corresponding 95% confidence intervals (CIs). The area under the receiver operating characteristic (AUC) curve derived from the data was taken to reflect the overall effectiveness of each quantitative method. Interstudy heterogeneity was formally tested using Cochran’s \(Q\) test, and significant heterogeneity was defined as \(P < 0.10\). We also examined the \(I^2\) statistic to reflect the heterogeneity of the included studies, which describes the percentage of total variation across studies that is due to heterogeneity rather than chance. An \(I^2 > 50\%\) was considered indicative of significant heterogeneity \[28\]. In cases of significant heterogeneity as reflected by \(I^2 > 50\%\), a random effects model was used to estimate the overall effect; otherwise, a fixed effects model was applied. Because the characteristics of controls may affect the diagnostic efficacy of circulating miR-122 for HCC, we subsequently analyzed the performance of miR-122 for discriminating HCC patients from healthy controls, from patients with HBV or HCV infection, and from patients with liver cirrhosis or dysplastic nodule formation. Deeks’ funnel plot asymmetry test was used to evaluate publication bias. Statistical analyses were performed using Stata 12.0. All statistical tests were two-sided, with \(P < 0.05\) indicating statistical significance.

3. Results

3.1. Studies Identified by Database Searches. The processes of database searching and study identification are summarized in Figure 1. Briefly, 751 studies were obtained from database searches, and 30 studies were kept after exclusion of 721 studies based on title and abstract screening for relevance. Seventeen studies were further excluded after full-text review, because they were animal studies \((n = 1)\), not designed as diagnostic studies \((n = 5)\), reported exosomal miR-122 expression rather than circulating miR-122 expression \((n = 3)\), evaluated single nucleotide polymorphisms of miR-122 \((n = 1)\), or reported diagnostic efficacies with no available data for miR-122 \((n = 7)\). Finally, 13 studies were included \[11\textendash}14, 16\textendash}24\].

3.2. Study Characteristics and Quality Evaluation. The characteristics of the included studies are summarized in Table 1. Overall, 13 studies reporting data for 920 patients with histopathologically confirmed HCC and 1217 control individuals were included. Seven of the studies were performed in China
Summary AUC was 0.91 (95% CI: 0.88–0.94). miR-122 for HCC versus HBV or HCV infection showed a sensitivity of 0.82 (95% CI: 0.66–0.91; Figure 2(c)). The summary AUC was 0.87 (95% CI: 0.84–0.90), according to the synthesized ROC curve (Figure 2(c)). Pooled results of six studies [14, 16, 17, 20, 22, 24] that evaluated the diagnostic performance of serum miR-122 for HCC versus liver cirrhosis or dysplastic nodule formation showed a sensitivity of 0.65 (95% CI: 0.56–0.73) and specificity of 0.75 (95% CI: 0.61–0.85; Figure 2(d)). The summary AUC was 0.74 (95% CI: 0.69–0.77), according to the synthesized ROC curve (Figure 2(d)).

4. Discussion

In this meta-analysis of 13 studies reporting data for 920 HCC patients and 1217 control individuals, we found that serum miR-122 conferred moderate diagnostic accuracy for HCC, with a summary AUC of 0.82. Subsequent analyses indicated that the serum miR-122 level confers acceptable efficacy for discriminating HCC patients from healthy controls (AUC: 0.91) or patients with HBV or HCV infection (AUC: 0.87), but less optimal efficacy for discriminating HCC patients from those with liver cirrhosis or dysplastic nodule formation (AUC: 0.74). These results suggest that measurement of serum miR-122 may be of significance for HCC surveillance in apparently healthy people or carriers of HBV or HCV, while for those with liver cirrhosis, imaging examinations are essential.

Previous findings from experimental studies indicated that miR-122 regulates various physiological and pathological processes within hepatic cells, such as lipid metabolism, the response to drug or alcoholic hepatic injury, the response to viral infection, and hepatic fibrosis formation [10]. Accumulating evidence indicates that miR-122 expression is downregulated in the HCC tissue comparing with the normal hepatic cells [29] and thus may predict poor prognosis in these patients [30]. Further studies have confirmed that miR-122 may function as a tumor suppressor during the process of hepatocarcinogenesis [31–33]. Interestingly, a higher level of circulating miR-122 has been observed in HCC patients versus those without HCC, suggesting serum miR-122 as a potential biomarker of HCC [8]. The results of our present meta-analysis further demonstrated that measurement of circulating miR-122 may confer moderate diagnostic efficacy for HCC according to histopathological examination, particularly for the discrimination of HCC patients from healthy controls or patients with HBV or HCV infection. These results are of clinical significance because they support the inclusion of serum miR-122 measurement in HCC surveillance in apparently healthy people or carriers of HBV or HCV.
| Author, year     | Country | Number of HCC patients | Mean age (years) of HCC patients | Male (%) among HCC patients | Control population | Number of controls | Control population | Mean age (years) of controls | Male (%) among controls | Sample type | miR measurement method | QUADAS score |
|------------------|---------|------------------------|----------------------------------|-----------------------------|---------------------|-------------------|-------------------|----------------------|------------------------|---------------|-------------------|---------------|
| Xu, 2011 [12]    | China   | 101                    | NR                               | 77.2                        | HC                  | 89                | NR                | 76.4                 | Serum                  | RT-qPCR       | 9                 |
| Qi, 2011 [11]    | China   | 70                     | 49.0                             | 78.6                        | HBV, HC             | 82                | 42.0              | 74.1                 | Serum                  | RT-qPCR       | 9                 |
| Luo, 2013 [13]   | China   | 85                     | 53.9                             | 82.4                        | HBV, HC             | 85                | 50.8              | 81.2                 | Serum                  | RT-qPCR       | 8                 |
| Tan, 2014 [14]   | China   | 135                    | 53.6                             | 83.0                        | LC, HBV             | 222               | 40.5              | 68.2                 | Serum                  | RT-qPCR       | 10                |
| El-Garem, 2014 [16] | Egypt | 30                     | 60.3                             | 83.3                        | LC                  | 30                | 55.1              | 70.0                 | Serum                  | RT-qPCR       | 6                 |
| Hung, 2016 [17]  | China   | 120                    | 58.5                             | 80.0                        | DN                  | 30                | 60.3              | 80.0                 | Serum                  | RT-qPCR       | 11                |
| Ali, 2017 [18]   | Egypt   | 34                     | NR                               | 76.5                        | HCV, HC             | 77                | NR                | 71.6                 | Serum                  | RT-qPCR       | 8                 |
| Amr, 2017a [19]  | Egypt   | 40                     | 52                               | 82.5                        | HCV, HC             | 60                | 50.0              | 83.0                 | Serum                  | RT-qPCR       | 9                 |
| Caviglia, 2017 [20] | Italy | 33                     | 63.0                             | 87.9                        | LC                  | 30                | 54.2              | 63.3                 | Serum                  | RT-qPCR       | 11                |
| Trung, 2018 [22] | Vietnam | 118                    | 55.6                             | 91.2                        | LC, HBV, HC         | 288               | 43.1              | 81.6                 | Serum                  | RT-qPCR       | 11                |
| An, 2018 [21]    | China   | 84                     | 52.7                             | 67.8                        | HC                  | 84                | 51.5              | 59.7                 | Serum                  | RT-qPCR       | 8                 |
| Weis, 2019 [24]  | Australia | 20                     | 58.3                             | 75.0                        | LC                  | 40                | 51.9              | 67.5                 | Serum                  | RT-qPCR       | 12                |
| Dai, 2019 [23]   | China   | 50                     | 48.6                             | 70.0                        | LC, HBV, HC         | 100               | 46.1              | 70.0                 | Serum                  | RT-qPCR       | 8                 |

HCC: hepatocellular carcinoma; NR: not reported; HC: healthy controls; HBV: hepatitis B virus infection; HCV: hepatitis C virus infection; LC: liver cirrhosis; DN: dysplastic nodule; RT-qPCR: reverse transcription quantitative real-time polymerase chain reaction; QUADAS: Quality Assessment of Diagnostic Accuracy Studies.
### Figure 2: Continued.

#### (a)

| Study ID     | Sensitivity (95% CI)     | Study ID     | Specificity (95% CI)     |
|--------------|--------------------------|--------------|--------------------------|
| Dai 2019     | 0.78 [0.64 – 0.88]       | Dai 2019     | 0.74 [0.64 – 0.82]       |
| Weiss 2019   | 0.75 [0.51 – 0.91]       | Weiss 2019   | 0.90 [0.76 – 0.97]       |
| An 2018      | 0.83 [0.74 – 0.91]       | An 2018      | 0.77 [0.67 – 0.86]       |
| Trung 2018   | 0.82 [0.74 – 0.89]       | Trung 2018   | 0.78 [0.73 – 0.83]       |
| Caviglia 2017| 0.61 [0.42 – 0.77]       | Caviglia 2017| 0.77 [0.58 – 0.90]       |
| Amr 2017     | 0.88 [0.73 – 0.96]       | Amr 2017     | 0.97 [0.88 – 1.00]       |
| Ali 2017     | 0.91 [0.76 – 0.98]       | Ali 2017     | 0.55 [0.43 – 0.66]       |
| Hung 2016    | 0.67 [0.57 – 0.75]       | Hung 2016    | 0.57 [0.37 – 0.75]       |
| El–Garem 2014| 0.83 [0.65 – 0.94]       | El–Garem 2014| 0.57 [0.37 – 0.75]       |
| Tan 2014     | 0.49 [0.40 – 0.58]       | Tan 2014     | 0.87 [0.82 – 0.91]       |
| Luo 2013     | 0.71 [0.60 – 0.80]       | Luo 2013     | 0.67 [0.56 – 0.77]       |
| Qi 2011      | 0.79 [0.67 – 0.87]       | Qi 2011      | 0.68 [0.57 – 0.78]       |
| Xu 2011      | 0.70 [0.60 – 0.79]       | Xu 2011      | 0.69 [0.58 – 0.78]       |
| Combined     | 0.76 [0.69 – 0.81]       | Combined     | 0.75 [0.67 – 0.82]       |

- $Q = 69.64$, $df = 12.00$, $P = 0.00$
- $I^2 = 82.77$ [74.29 – 91.25]

#### (b)

| Study ID     | Sensitivity (95% CI)     | Study ID     | Specificity (95% CI)     |
|--------------|--------------------------|--------------|--------------------------|
| Dai 2019     | 0.90 [0.78 – 0.97]       | Dai 2019     | 0.86 [0.73 – 0.94]       |
| An 2018      | 0.83 [0.74 – 0.91]       | An 2018      | 0.77 [0.67 – 0.86]       |
| Amr 2017     | 0.88 [0.73 – 0.96]       | Amr 2017     | 0.95 [0.75 – 1.00]       |
| Ali 2017     | 0.94 [0.80 – 0.99]       | Ali 2017     | 0.92 [0.74 – 0.99]       |
| Qi 2011      | 0.81 [0.70 – 0.90]       | Qi 2011      | 0.82 [0.65 – 0.93]       |
| Xu 2011      | 0.70 [0.60 – 0.79]       | Xu 2011      | 0.69 [0.58 – 0.78]       |
| Combined     | 0.85 [0.77 – 0.90]       | Combined     | 0.83 [0.74 – 0.89]       |

- $Q = 21.40$, $df = 5.00$, $P = 0.00$
- $I^2 = 76.63$ [57.83 – 95.43]

- $Q = 19.05$, $df = 5.00$, $P = 0.00$
- $I^2 = 73.75$ [52.06 – 95.44]
### Figure 2: Forest plots for the diagnostic performance of circulating miR-122 for HCC

(a) summarized sensitivity and specificity of serum miR-122 for discriminating HCC patients from overall controls; (b) summarized sensitivity and specificity of serum miR-122 for discriminating HCC patients from healthy controls; (c) summarized sensitivity and specificity of serum miR-122 for discriminating HCC patients from patients with HBV or HCV infection; (d) summarized sensitivity and specificity of serum miR-122 for discriminating HCC patients from patients with liver cirrhosis or dysplastic nodule formation.

**Panel (a):**

| Study ID | Sensitivity (95% CI) | Specificity (95% CI) |
|----------|----------------------|----------------------|
| Trung 2018 | 0.89 [0.82 – 0.94] | 0.71 [0.61 – 0.80] |
| Amr 2017 | 0.88 [0.73 – 0.96] | 0.98 [0.87 – 1.00] |
| Ali 2017 | 0.82 [0.65 – 0.93] | 0.85 [0.72 – 0.93] |
| Tan 2014 | 0.49 [0.40 – 0.58] | 0.83 [0.74 – 0.90] |
| Qi 2011 | 0.77 [0.66 – 0.86] | 0.58 [0.43 – 0.72] |
| Combined | 0.79 [0.64 – 0.89] | 0.82 [0.66 – 0.91] |

Q = 75.29, df = 4.00, P = 0.00

I² = 94.69 [91.51 – 97.86]

**Panel (b):**

| Study ID | Sensitivity (95% CI) | Specificity (95% CI) |
|----------|----------------------|----------------------|
| Combined | 0.79 [0.64 – 0.89] | 0.82 [0.66 – 0.91] |

Q = 30.07, df = 4.00, P = 0.00

I² = 86.70 [76.40 – 96.99]

**Panel (c):**

| Study ID | Sensitivity (95% CI) | Specificity (95% CI) |
|----------|----------------------|----------------------|
| Combined | 0.79 [0.64 – 0.89] | 0.82 [0.66 – 0.91] |

Q = 30.07, df = 4.00, P = 0.00

I² = 86.70 [76.40 – 96.99]

**Panel (d):**

| Study ID | Sensitivity (95% CI) | Specificity (95% CI) |
|----------|----------------------|----------------------|
| Combined | 0.79 [0.64 – 0.89] | 0.82 [0.66 – 0.91] |

Q = 23.08, df = 5.00, P = 0.00

I² = 78.34 [61.22 – 95.45]

**Panel (d):**

| Study ID | Sensitivity (95% CI) | Specificity (95% CI) |
|----------|----------------------|----------------------|
| Combined | 0.79 [0.64 – 0.89] | 0.82 [0.66 – 0.91] |

Q = 23.08, df = 5.00, P = 0.00

I² = 78.34 [61.22 – 95.45]

**Panel (d):**

| Study ID | Sensitivity (95% CI) | Specificity (95% CI) |
|----------|----------------------|----------------------|
| Combined | 0.79 [0.64 – 0.89] | 0.82 [0.66 – 0.91] |

Q = 23.08, df = 5.00, P = 0.00

I² = 78.34 [61.22 – 95.45]

**Panel (d):**

| Study ID | Sensitivity (95% CI) | Specificity (95% CI) |
|----------|----------------------|----------------------|
| Combined | 0.79 [0.64 – 0.89] | 0.82 [0.66 – 0.91] |

Q = 23.08, df = 5.00, P = 0.00

I² = 78.34 [61.22 – 95.45]

**Panel (d):**

| Study ID | Sensitivity (95% CI) | Specificity (95% CI) |
|----------|----------------------|----------------------|
| Combined | 0.79 [0.64 – 0.89] | 0.82 [0.66 – 0.91] |

Q = 23.08, df = 5.00, P = 0.00

I² = 78.34 [61.22 – 95.45]
Figure 3: ROC curves for the diagnostic performance of circulating miR-122 for HCC: (a) summarized ROC curves for the ability of serum miR-122 to distinguish HCC patients from overall controls; (b) summarized ROC curves for the ability of serum miR-122 to distinguish HCC patients from healthy controls; (c) summarized ROC curves for the ability of serum miR-122 to distinguish HCC patients from patients with HBV or HCV infection; (d) summarized ROC curves for the ability of serum miR-122 to distinguish HCC patients from patients with liver cirrhosis or dysplastic nodule formation.
Moreover, for patients with already confirmed liver diseases such as liver cirrhosis, measurement of serum miR-122 may not be adequate for screening for HCC, and imaging examinations such as abdominal CT or MRI are essential for these patients. In addition, measurement of serum miR-122 for HCC surveillance has a few advantages similar to other miRNA biomarkers, as their measurement is noninvasive, stable, and reproducible [34]. The optimal protocol for...

**Figure 4:** Deeks’ funnel plots for the estimation of publication bias among studies evaluating the diagnostic performance of circulating miR-122 for HCC: (a) Deeks’ funnel plots for meta-analysis of serum miR-122 for discriminating HCC patients from overall controls; (b) Deeks’ funnel plots for meta-analysis of serum miR-122 for discriminating HCC patients from healthy controls; (c) Deeks’ funnel plots for meta-analysis of serum miR-122 for discriminating HCC patients from patients with HBV or HCV infection; (d) Deeks’ funnel plots for meta-analysis of serum miR-122 for discriminating HCC patients from patients with liver cirrhosis or dysplastic nodule formation.
circulating miR-122 measurement and its cutoff value for diagnosis of HCC in different populations deserve further evaluation.

To the best of our knowledge, only one previous meta-analysis evaluated the diagnostic role of miR-122 for HCC. This meta-analysis only included four available studies published before 2015 and concluded that miR-122 may be used to distinguish HCC patients from healthy controls. Our meta-analysis included a total of 13 studies with 920 HCC patients and 1217 controls. The larger datasets enable our study to confirm the discriminating role of circulating miR-122 for HCC from healthy controls, with comprehensively summarized diagnostic parameters including sensitivities, specificities, and AUCs. Compared to healthy controls, discriminating patients with HCC from high-risk population, such as those with HBV/HCV infection or liver cirrhosis or dysplastic nodule formation, is of more clinical importance [35, 36]. Although previous meta-analysis suggested a discriminating role of circulating miR-122 for HCC from healthy controls, its ability for the discriminating of HCC from high-risk population remains undetermined. Our meta-analysis showed that miR-122 may be useful to discriminate HCC from patients with HBV or HCV infection (AUC: 0.87), but with less optimal efficacy for discriminating HCC patients from those with liver cirrhosis or dysplastic nodule formation (AUC: 0.74). These results demonstrated that serum miR-122 may be of significance for HCC surveillance in apparently healthy people, but for patients with liver cirrhosis or dysplastic nodule formation, additional strategies are required.

Our study also has a few limitations. First, the heterogeneity among the included studies was considerable based on the I² statistics and results of Cochran’s Q tests. Differences in study characteristics, such as comorbidities of the patients, miR-122 cutoff values, and internal controls used during quantitative PCR, may contribute to the heterogeneity. Unfortunately, we were unable to explore the influences of the above factors on the results of the meta-analysis, because these factors were rarely reported in the included studies. Secondly, the diagnostic performance of circulating miR-122 for HCC was only moderate based on our results. Strategies to improve this efficacy deserve investigation. For example, recent studies indicated that the measurement of miR-122 from circulating exosomes may provide better diagnostic efficacy for HCC than the measurement of miR-122 in serum [37, 38]. Other strategies such as using miRNA panels [39] or combining conventional diagnostic strategies with circulating miR-122 measurement [40] may also improve the diagnostic efficacy for HCC. Finally, because the incidence of HCC is high in Chinese patients, a large proportion of studies regarding HCC diagnosis and prevention have been performed in China, as reflected in our meta-analysis. The potential diagnostic efficacy of circulating miR-122 for HCC in patients from other countries deserves further evaluation.

In conclusion, the results of our study indicate that serum miR-122 confers moderate efficacy for discriminating HCC patients from healthy controls or patients with HBV or HCV infection, but not for discriminating HCC patients from patients with liver cirrhosis or dysplastic nodule formation. Measurement of serum miR-122 may be of significance for HCC surveillance in apparently healthy people.

Data Availability
The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest
The authors declared that they have no conflict of interest.

Acknowledgments
This study was supported by Beijing Municipal Administration of Hospitals’ Clinical Medicine Development Special Funding (no. YMLX201711).

References
[1] A. Villanueva, “Hepatocellular carcinoma,” New England Journal of Medicine, vol. 380, no. 15, pp. 1450–1462, 2019.
[2] P. Song, Y. Cai, H. Tang, C. Li, and J. Huang, "The clinical management of hepatocellular carcinoma worldwide: a concise review and comparison of current guidelines from 2001 to 2017,” Bioscience Trends, vol. 11, no. 4, pp. 389–398, 2017.
[3] P. S. Harris, R. M. Hansen, M. E. Gray, O. I. Massoud, B. McGuire, and M. G. Shoreibah, “Hepatocellular carcinoma surveillance: an evidence-based approach,” World Journal of Gastroenterology, vol. 25, no. 13, pp. 1550–1559, 2019.
[4] P. J. Navin and S. K. Venkatesh, “Hepatocellular carcinoma: state of the art imaging and recent advances,” Journal of Clinical and Translational Hepatology, vol. 7, no. 1, pp. 72–85, 2019.
[5] M. Ronot, Y. Purcell, and V. Vilgrain, “Hepatocellular carcinoma: current imaging modalities for diagnosis and prognosis,” Digestive Diseases and Sciences, vol. 64, no. 4, pp. 934–950, 2019.
[6] R. J. Wong, A. Ahmed, and R. G. Gish, “Elevated alpha-fetoprotein: differential diagnosis-hepatocellular carcinoma and other disorders,” Clinics in Liver Disease, vol. 19, no. 2, pp. 309–323, 2015.
[7] R. Rupaimoole and F. J. Slack, “MicroRNA therapeutics: towards a new era for the management of cancer and other diseases,” Nature Reviews Drug Discovery, vol. 16, no. 3, pp. 203–222, 2017.
[8] S. M. Parizadeh, R. Jafarzadeh-Esfahani, M. Ghandehari et al., “MicroRNAs as potential diagnostic and prognostic biomarkers in hepatocellular carcinoma,” Current Drug Targets, vol. 20, no. 11, pp. 1129–1140, 2019.
[9] G. Ors-Kumoglu, S. Gulce-Iz, and C. Biray-Avci, “Therapeutic microRNAs in human cancer,” Cytotechnology, vol. 71, no. 1, pp. 411–425, 2019.
[10] S. Bandiera, S. Peerf, T. F. Baumert, and M. B. Zeisel, “miR-122—a key factor and therapeutic target in liver disease,” Journal of Hepatology, vol. 62, no. 2, pp. 448–457, 2015.
[11] P. Qi, S. Q. Cheng, H. Wang, N. Li, Y. F. Chen, and C. F. Gao, “Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection,” PLoS One, vol. 6, no. 12, article e28486, 2011.
[12] J. Xu, C. Wu, X. Che et al., “Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis,” Molecular Carcinogenesis, vol. 50, no. 2, pp. 136–142, 2011.

[13] J. Luo, M. Chen, H. Huang et al., “Circulating microRNA-122a as a diagnostic marker for hepatocellular carcinoma,” Onco- Targets and Therapy, vol. 6, pp. 577–583, 2013.

[14] Y. Tan, G. Ge, T. Pan et al., “A serum microRNA panel as potential biomarkers for hepatocellular carcinoma related with hepatitis B virus,” PLoS One, vol. 9, no. 9, article e107986, 2014.

[15] J. T. Huang, S. M. Liu, H. Ma et al., “Systematic review and meta-analysis: circulating miRNAs for diagnosis of hepatocellular carcinoma,” Journal of Cellular Physiology, vol. 231, no. 2, pp. 328–335, 2016.

[16] H. El-Garem, A. Ammer, H. Shehab et al., “Circulating microRNA, miR-122 and miR-221 signature in Egyptian patients with chronic hepatitis C related hepatocellular carcinoma,” World Journal of Hepatology, vol. 6, no. 11, pp. 818–824, 2014.

[17] C. H. Hung, T. H. Hu, S. N. Lu et al., “Circulating microRNAs as biomarkers for diagnosis of early hepatocellular carcinoma associated with hepatitis B virus,” International Journal of Cancer, vol. 138, no. 3, pp. 714–720, 2014.

[18] H. E. A. Ali, R. Abdel Hameed, H. Effat et al., “Circulating microRNAs panel as a diagnostic tool for discrimination of HCV-associated hepatocellular carcinoma,” Clinics and Research in Hepatology and Gastroenterology, vol. 41, no. 4, pp. e51–e62, 2017.

[19] K. S. Amr, H. A. Elmawgoud Atia, R. A. Elaazem Elbnhawy, and W. M. Ezzat, “Early diagnostic evaluation of miR-122 and miR-224 as biomarkers for hepatocellular carcinoma,” Genes & Diseases, vol. 4, no. 4, pp. 215–221, 2017.

[20] G. P. Caviglia, M. L. Abate, S. Gaia et al., “Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II,” Panminerva Medica, vol. 59, no. 4, pp. 283–289, 2017.

[21] Y. An, S. Gao, W. C. Zhao et al., “Novel serum microRNAs panel on the diagnostic and prognostic implications of hepatocellular carcinoma,” World Journal of Gastroenterology, vol. 24, no. 24, pp. 2596–2604, 2018.

[22] N. Tat Trung, D. C. Duong, H. V. Tong et al., “Optimisation of quantitative miRNA panels to consolidate the diagnostic surveillance of HBV-related hepatocellular carcinoma,” PLoS One, vol. 13, no. 4, article e0196081, 2018.

[23] M. Dai, L. Li, and X. Qin, “Clinical value of miRNA-122 in the diagnosis and prognosis of various types of cancer,” Oncology Letters, vol. 17, no. 4, pp. 3919–3929, 2019.

[24] A. Weis, L. Marquart, D. A. Calvopina, B. Genz, G. Ramm, and R. Skoien, “Serum microRNAs as biomarkers in hepatitis C: preliminary evidence of a microRNA panel for the diagnosis of hepatocellular carcinoma,” International Journal of Molecular Sciences, vol. 20, no. 4, p. 864, 2019.

[25] D. Moher, A. Liberati, J. Tetzlaff, D. G. Altman, and for the PRISMA Group, "Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement," BMJ, vol. 339, no. jul21 1, p. b2535, 2009.

[26] J. Higgins and S. Green, Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0, The Cochrane Collaboration, 2011, http://www.cochranehandbook.org/.

[27] P. Whiting, A. W. S. Rutjes, J. B. Reitsma, P. M. M. Bossuyt, and J. Kleijnen, "The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews," BMC Medical Research Methodology, vol. 3, no. 1, p. 25, 2003.

[28] J. P. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman, “Measuring inconsistency in meta-analyses,” BMJ, vol. 327, no. 7414, pp. 557–560, 2003.

[29] H. Kutay, S. Bai, J. Datta et al., “Downregulation of miR-122 in the rodent and human hepatocellular carcinomas,” Journal of Cellular Biochemistry, vol. 99, no. 3, pp. 671–678, 2006.

[30] Y. Zhang, Y. Li, W. Jiang, Q. Li, and Y. Lan, “The clinical significance of microRNA-122 in predicting the prognosis of patients with hepatocellular carcinoma: a meta-analysis validated by the Cancer Genome Atlas dataset,” Medicine, vol. 98, no. 13, article e14810, 2019.

[31] S. Bai, M. W. Nasser, B. Wang et al., “MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib,” The Journal of Biological Chemistry, vol. 284, no. 46, pp. 32015–32027, 2009.

[32] C. J. Lin, H. Y. Gong, H. C. Tseng, W. L. Wang, and J. L. Wu, “miR-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines,” Biochemical and Biophysical Research Communications, vol. 375, no. 3, pp. 315–320, 2008.

[33] W. C. Tsai, P. W. Hsu, T. C. Lai et al., “MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma,” Hepatology, vol. 49, no. 5, pp. 1571–1582, 2009.

[34] M. Redova, J. Sana, and O. Slaby, “Circulating miRNAs as new blood-based biomarkers for solid cancers,” Future Oncology, vol. 9, no. 3, pp. 387–402, 2013.

[35] F. Kanwal and A. G. Singal, “Surveillance for hepatocellular carcinoma: current best practice and future direction,” Gastroenterology, vol. 157, no. 1, pp. 54–64, 2019.

[36] A. Bailey and S. A. Shah, “Screening high risk populations for cancer: hepatobiliary,” Journal of Surgical Oncology, vol. 120, no. 5, pp. 847–850, 2019.

[37] Y. Wang, C. Zhang, P. Zhang et al., “Serum exosomal microRNAs combined with alpha-fetoprotein as diagnostic markers of hepatocellular carcinoma,” Cancer Medicine, vol. 7, no. 5, pp. 1670–1679, 2018.

[38] X. Xue, Y. Zhao, X. Wang, L. Qin, and R. Hu, “Development and validation of serum exosomal microRNAs as diagnostic and prognostic biomarkers for hepatocellular carcinoma,” Journal of Cellular Biochemistry, vol. 120, no. 1, pp. 135–142, 2019.

[39] C. Peng, Y. Ye, Z. Wang et al., “Circulating microRNAs for the diagnosis of hepatocellular carcinoma,” Digestive and Liver Disease, vol. 51, no. 5, pp. 621–631, 2019.

[40] H. Yu, R. Han, J. Su, H. Chen, and D. Li, “Multi-marker diagnosis method for early hepatocellular carcinoma based on surface plasmon resonance,” Clinica Chimica Acta, vol. 502, pp. 9–14, 2019.